Journal of Neuroimmune Pharmacology

, Volume 2, Issue 1, pp 105–111 | Cite as

Assessment of NeuroAIDS in the International Setting

Invited Review


The global burden of the HIV epidemic is staggering, but in the short term, it is largely unfelt in the developed world. Almost one million people have been infected with HIV in North America, and the results of effective antiretroviral therapy have dramatically improved survival and quality of life. However, there are 25 million infected in sub-Saharan Africa alone, and antiretroviral treatment is scarce. Ninety-five percent of new infections occur in the developing world where resources are limited. Very little is known about NeuroAIDS in the developing world where few studies have been conducted on the neurologic and neurocognitive effects of antiretroviral treatment. HIV Clade differences and other factors could have dramatic effects on treatment effectiveness. There are a number of barriers in the assessment of neurological and neurocognitive effects in resource limited settings and some of these will be addressed.


neuroAIDS HIV AIDS neurological neuropsychological resource-limited HAART 


  1. AAN (1991) Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. In: Neurology, pp 778–785Google Scholar
  2. Belec L, Martin PM, Vohito MD, Gresenguet G, Tabo A, Georges AJ (1989) Low prevalence of neuro-psychiatric clinical manifestations in central African patients with acquired immune deficiency syndrome. Trans R Soc Trop Med Hyg 83:844–846PubMedCrossRefGoogle Scholar
  3. Brew BJ (2003) The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve 28:542–552PubMedCrossRefGoogle Scholar
  4. Clifford D, Evans S (2006) Ethiopian NeuroAIDS Assessment. In: Assessment of NeuroAIDS in Africa. Arusha, TanzaniaGoogle Scholar
  5. Deutsch R, Ellis RJ, McCutchan JA, Marcotte TD, Letendre S, Grant I (2001) AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS 15:1898–1899PubMedCrossRefGoogle Scholar
  6. Elder GA, Sever JL (1988) AIDS and neurological disorders: an overview. Ann Neurol 23(Suppl):S4–S6PubMedCrossRefGoogle Scholar
  7. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436–441PubMedCrossRefGoogle Scholar
  8. Gendelman HE, Zheng J, Coulter CL, Ghorpade A, Che M, Thylin M, Rubocki R, Persidsky Y, Hahn F, Reinhard J Jr, Swindells S (1998) Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 178:1000–1007PubMedGoogle Scholar
  9. Grant I (2006) Studies of Neurologic Complications of HIV in China, India and Brazil. In: Assessment of Resources and Opportunities for NeuroAIDS research in Nigeria/West Africa and Central Africa. Abuja, NigeriaGoogle Scholar
  10. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I (2004) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10:317–331PubMedCrossRefGoogle Scholar
  11. Howlett WP, Nkya WM, Mmuni KA, Missalek WR (1989) Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. AIDS 3:289–296PubMedCrossRefGoogle Scholar
  12. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J (2002) Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 185:1244–1250PubMedCrossRefGoogle Scholar
  13. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, Woodcock SA, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, Ndoye I, Essex ME, Mboup S (1999) Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179:68–73PubMedCrossRefGoogle Scholar
  14. Laeyendecker O, Li X, Arroyo R, McCutchan F, Gray R, Wawer M et al. (2006) The effect of HIV subtype on rapid disease progression in Rakai, Uganda. In: CROI. DenverGoogle Scholar
  15. Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, Letendre S, Grant I, McCutchan JA, Masliah E, Ellis RJ (2006) Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 12:100–107PubMedCrossRefGoogle Scholar
  16. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ (2004) Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56:416–423PubMedCrossRefGoogle Scholar
  17. Maj M, Satz P, Janssen R, Zaudig M, Starace F, D’Elia L, Sughondhabirom B, Mussa M, Naber D, Ndetei D, et al. (1994) WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry 51:51–61PubMedGoogle Scholar
  18. Marcotte TD, Wolfson T, Rosenthal TJ, Heaton RK, Gonzalez R, Ellis RJ, Grant I (2004) A multimodal assessment of driving performance in HIV infection. Neurology 63:1417–1422PubMedGoogle Scholar
  19. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N (2003) Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirology 9:205–221Google Scholar
  20. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP, et al. (1993) Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43:2245–2252PubMedGoogle Scholar
  21. Nakasujja N, Wong M, Robertson K, McArthur J, Sacktor N (2004) HIV-associated neurological complications among HIV-seropositive individuals in Uganda. Neurology 62:A444Google Scholar
  22. Navia BA, Jordan BD, Price RW (1986a) The AIDS dementia complex: I. Clinical features. Ann Neurol 19:517–524PubMedCrossRefGoogle Scholar
  23. Navia BA, Cho ES, Petito CK, Price RW (1986b) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19:525–535PubMedCrossRefGoogle Scholar
  24. Robertson KR, Hall CD (1992) Human immunodeficiency virus-related cognitive impairment and the acquired immunodeficiency syndrome dementia complex. Semin Neurol 12:18–27PubMedCrossRefGoogle Scholar
  25. Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD (2004) Highly active antiretroviral therapy improves neurocognitive functioning. AIDS 36:562–566Google Scholar
  26. Sacktor N (2006) Assessment of HIV dementia in Uganda: results from the academic alliance cohort. In: Assessment of NeuroAIDS in Africa. Arusha, TanzaniaGoogle Scholar
  27. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirology 8:136–142Google Scholar
  28. Schifitto G, Kieburtz K, McDermott MP, McArthur J, Marder K, Sacktor N, Palumbo D, Selnes O, Stern Y, Epstein L, Albert S (2001) Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 56:415–418PubMedGoogle Scholar
  29. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, Letendre S, Videen JS, McCutchan JA, Patterson TL, Grant I (2005) Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirology 11:356–364CrossRefGoogle Scholar
  30. Shiramizu B, Nidhinandana S, Sithinamsuwan P, Sataporn T, Apateerapong W, Ratto-Kim S, Chitpatima S, Robertson K, Troelstrup D, Anderson E, Shikuma C, Valcour V (2006 (February)) HIV DNA Correlates with HIV-1-Associated Dementia in Patients in Bangkok, Thailand. In: 13th Conference of Retrovirology and Opportunistic Infections. Denver, CO, USAGoogle Scholar
  31. Simpson DM, Haidich AB, Schifitto G, Yiannoutsos CT, Geraci AP, McArthur JC, Katzenstein DA (2002) Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 16:407–412PubMedCrossRefGoogle Scholar
  32. Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, Antinori A, Giulianelli M, Tosi G, Costa M, Sampaolesi A, Fantoni M, Noto P, Ippolito G, Wu AW (2003) Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses 19:643–652PubMedCrossRefGoogle Scholar
  33. UNAIDS (2003) Global summary of the HIV/AIDS epidemic. In: UNAIDS, Geneva, SwitzerlandGoogle Scholar
  34. Valcour V, Nidhinandana S, Sithinamsuwan P, Thitivichianlert S, Apateerapong W, Ratto-Kim S, Kim J, Shiramizu B, Chitpatima S, Sukwit S, Chuenchitra T, Watt G, Robertson K, Paul R, Shikuma C (2005) Neuropsychological testing abnormalities among HIV patients in Bangkok, Thailand. In: Conference on HIV infection and the central nervous system: developed and resource-limited settings. Frascati, ItalyGoogle Scholar
  35. Van Rie A, Mupuala A, Dow Nosse N, Zephyrin I, Kilese N (2006) HIV/AIDS and neurodevelopment in sub-Saharan Africa. In: Assessment of NeuroAIDS in Africa. Arusha, TanzaniaGoogle Scholar
  36. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, Fawzi W, Hunter D (2006) Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 42:843–852PubMedCrossRefGoogle Scholar
  37. Wainberg MA (2004) HIV-1 subtype distribution and the problem of drug resistance. AIDS 18(Suppl 3):S63–68PubMedCrossRefGoogle Scholar
  38. Wright E, Brew B, Lal L, Imran D, Lun W, Kamarulzaman A, Lim M, Robertson K, McArthur J, Wesselingh S, the APNAC Study Protocol Team (2006) Neurocognitive impairment, symptomatic peripheral neuropathy, and depression in HIV-infected outpatients within the Asia Pacific Region: Findings of the APNAC Study. In: 13th conference on retroviruses and opportunistic infections. Denver, CO, USAGoogle Scholar
  39. Yepthomi T, Paul R, Vallabhaneni S, Kumarasamy N, Tate DF, Solomon S, Flanigan T (2006) Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. J Int Neuropsychol Soc 12:424–430PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  1. 1.Neurology, School of MedicineUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.3114 Bioinformatics, Neurology CB7025School of Medicine, UNCChapel HillUSA

Personalised recommendations